Literature DB >> 10195080

Glucocorticoid insensitive asthma: a one year clinical follow up pilot study.

P Demoly1, D Jaffuel, M Mathieu, H Sahla, P Godard, F B Michel, J Bousquet.   

Abstract

BACKGROUND: Glucocorticoid resistant or insensitive asthmatic subjects are usually defined as patients whose baseline pre-bronchodilation forced expiratory volume in one second (FEV1) of less than 70-80% predicted improves significantly in response to beta 2 agonists but by less than 15% following 1-2 weeks of 40 mg prednisolone daily. Since there is little long term clinical information on these patients, a one year prospective study was performed to assess whether glucocorticoid sensitivity may vary over time.
METHODS: Nineteen severe asthmatic subjects were studied and received 40 mg prednisolone daily for seven days. Prednisolone was given for a further seven days in glucocorticoid insensitive asthmatics and then stopped. Patients were followed up for one year and the glucocorticoid test was repeated on five patients in each group six months later.
RESULTS: Eleven patients were classified as glucocorticoid insensitive and eight as glucocorticoid sensitive on day 7. The demographic characteristics of the patients were similar in both groups. Four glucocorticoid insensitive patients became responsive after one further week of prednisolone treatment. Six months later, four of five glucocorticoid sensitive patients and three of five previously glucocorticoid insensitive patients were glucocorticoid sensitive.
CONCLUSIONS: Glucocorticoid sensitivity varies over time.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10195080      PMCID: PMC1745126          DOI: 10.1136/thx.53.12.1063

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  Comparison of three different oral corticosteroids in steroid-dependent asthma patients.

Authors:  P Chanez; L Paradis; A Des Roches; F Paganin; M Bashir; P Godard; J Bousquet
Journal:  Allergy       Date:  1996-11       Impact factor: 13.146

2.  Penetration of corticosteroids into the lung: evidence for a difference between methylprednisolone and prednisolone.

Authors:  P Vichyanond; C G Irvin; G L Larsen; S J Szefler; M R Hill
Journal:  J Allergy Clin Immunol       Date:  1989-12       Impact factor: 10.793

3.  High-dose and low-dose systemic corticosteroids are equally efficient in acute severe asthma.

Authors:  C H Marquette; B Stach; E Cardot; J F Bervar; F Saulnier; J J Lafitte; P Goldstein; B Wallaert; A B Tonnel
Journal:  Eur Respir J       Date:  1995-01       Impact factor: 16.671

4.  Assessment of the severity of asthma by an expert system. Description and evaluation.

Authors:  H Redier; J P Daures; C Michel; H Proudhon; D Vervloet; D Charpin; J Marsac; D Dusser; C Brambilla; B Wallaert
Journal:  Am J Respir Crit Care Med       Date:  1995-02       Impact factor: 21.405

5.  Eosinophilic inflammation in asthma.

Authors:  J Bousquet; P Chanez; J Y Lacoste; G Barnéon; N Ghavanian; I Enander; P Venge; S Ahlstedt; J Simony-Lafontaine; P Godard
Journal:  N Engl J Med       Date:  1990-10-11       Impact factor: 91.245

6.  Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics.

Authors:  S R Nimmagadda; S J Szefler; J D Spahn; W Surs; D Y Leung
Journal:  Am J Respir Crit Care Med       Date:  1997-01       Impact factor: 21.405

7.  Effect of betamethasone on airway obstruction and bronchial response to salbutamol in prednisolone resistant asthma.

Authors:  B Grandordy; N Belmatoug; A Morelle; D De Lauture; J Marsac
Journal:  Thorax       Date:  1987-01       Impact factor: 9.139

8.  Prednisone and methylprednisolone disposition in the lung.

Authors:  A C Braude; A S Rebuck
Journal:  Lancet       Date:  1983-10-29       Impact factor: 79.321

  8 in total
  1 in total

1.  Clinical and molecular aspects of glucocorticoid resistant asthma.

Authors:  Chris J Corrigan; Tuck-Kay Loke
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.